AU2001226346A1 - Pseudopolymorph of - Google Patents

Pseudopolymorph of

Info

Publication number
AU2001226346A1
AU2001226346A1 AU2001226346A AU2634601A AU2001226346A1 AU 2001226346 A1 AU2001226346 A1 AU 2001226346A1 AU 2001226346 A AU2001226346 A AU 2001226346A AU 2634601 A AU2634601 A AU 2634601A AU 2001226346 A1 AU2001226346 A1 AU 2001226346A1
Authority
AU
Australia
Prior art keywords
pseudopolymorph
benzopyran
piperidinyl
chlorophenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001226346A
Other languages
English (en)
Inventor
Gary L. Bafus
Christine M. Harrison-Bowman
Gary L. Silvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU2001226346A1 publication Critical patent/AU2001226346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Stereophonic System (AREA)
  • Inorganic Insulating Materials (AREA)
  • Hydrogenated Pyridines (AREA)
AU2001226346A 2000-01-18 2001-01-08 Pseudopolymorph of Abandoned AU2001226346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48471700A 2000-01-18 2000-01-18
US09484717 2000-01-18
PCT/US2001/000519 WO2001053293A1 (en) 2000-01-18 2001-01-08 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one

Publications (1)

Publication Number Publication Date
AU2001226346A1 true AU2001226346A1 (en) 2001-07-31

Family

ID=23925305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001226346A Abandoned AU2001226346A1 (en) 2000-01-18 2001-01-08 Pseudopolymorph of

Country Status (26)

Country Link
EP (1) EP1259507B1 (zh)
JP (1) JP2003520797A (zh)
KR (1) KR100806464B1 (zh)
CN (1) CN1174977C (zh)
AT (1) ATE273303T1 (zh)
AU (1) AU2001226346A1 (zh)
BR (1) BR0107726A (zh)
CA (1) CA2397593C (zh)
CZ (1) CZ301195B6 (zh)
DE (1) DE60104822T2 (zh)
DK (1) DK1259507T3 (zh)
EA (1) EA005247B1 (zh)
ES (1) ES2222332T3 (zh)
HU (1) HUP0204126A3 (zh)
IL (2) IL150638A0 (zh)
MX (1) MXPA02007005A (zh)
NO (1) NO322572B1 (zh)
NZ (1) NZ520280A (zh)
PL (1) PL200696B1 (zh)
PT (1) PT1259507E (zh)
SI (1) SI1259507T1 (zh)
SK (1) SK287404B6 (zh)
TR (1) TR200402036T4 (zh)
TW (1) TWI284129B (zh)
WO (1) WO2001053293A1 (zh)
ZA (1) ZA200205639B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264950B2 (en) 2016-08-23 2024-01-01 Eisai R&D Man Co Ltd Combined treatments for the treatment of malignant liver cell carcinoma
IL269357B1 (en) 2017-03-16 2024-06-01 Eisai R&D Man Co Ltd A combination of Era inhibitors and a CDK4/6 inhibitor to be used in a method to treat breast cancer
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (zh) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Also Published As

Publication number Publication date
TWI284129B (en) 2007-07-21
TR200402036T4 (tr) 2004-10-21
DK1259507T3 (da) 2004-11-01
SI1259507T1 (en) 2005-02-28
JP2003520797A (ja) 2003-07-08
ES2222332T3 (es) 2005-02-01
PL200696B1 (pl) 2009-01-30
CN1174977C (zh) 2004-11-10
EA200200775A1 (ru) 2002-12-26
NZ520280A (en) 2004-04-30
SK10362002A3 (sk) 2003-01-09
CA2397593C (en) 2009-11-10
ATE273303T1 (de) 2004-08-15
EP1259507A1 (en) 2002-11-27
KR20020069361A (ko) 2002-08-30
EA005247B1 (ru) 2004-12-30
EP1259507B1 (en) 2004-08-11
CA2397593A1 (en) 2001-07-26
NO322572B1 (no) 2006-10-30
PT1259507E (pt) 2004-12-31
HUP0204126A2 (hu) 2003-04-28
DE60104822D1 (de) 2004-09-16
WO2001053293A1 (en) 2001-07-26
IL150638A0 (en) 2003-02-12
KR100806464B1 (ko) 2008-02-21
NO20023386D0 (no) 2002-07-12
NO20023386L (no) 2002-09-12
CN1395576A (zh) 2003-02-05
ZA200205639B (en) 2003-10-15
DE60104822T2 (de) 2005-09-01
PL356165A1 (en) 2004-06-14
IL150638A (en) 2009-06-15
MXPA02007005A (es) 2004-09-06
CZ20022466A3 (cs) 2002-11-13
BR0107726A (pt) 2002-10-01
HUP0204126A3 (en) 2006-02-28
CZ301195B6 (cs) 2009-12-02
SK287404B6 (sk) 2010-09-07

Similar Documents

Publication Publication Date Title
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU2002224154A1 (en) Method for producing polybutene
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2002353979A1 (en) Environmentally resistant block and method of using same
AU6397301A (en) Synchronization method
AU4859001A (en) Method of evaluating queries against received event information
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2001226346A1 (en) Pseudopolymorph of
AU2002322838A1 (en) Low sensitivity explosive compositions and method for making explosive compositions
AU2002224322A1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease
AU7965301A (en) Method for producing polyisobutenes
PL355992A1 (en) Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
AU2001261260A1 (en) Methods for accelerated desensitization of teeth
AU2002214920A1 (en) Composition for aids and method producing it
AU2001267389A1 (en) Method for producing cyclic lactams
AU2002227952A1 (en) Klainetin and derivatives thereof, method for their production and the use of the same
AU2001270741A1 (en) Steel compositions, method for obtaining same and parts made from same
AU2001268110A1 (en) Methods for isolating and using fungal hemolysins
AU2001261116A1 (en) Method and compositions for drug discovery
AU4164899A (en) Method of hydrogenating block copolymer
AU2001255339A1 (en) Systems, kits, and methods of administering synthetic plasma
AU2001278703A1 (en) Process for the production of block copolymers, block copolymers produced by the process, and use of the copolymers
AU2001289851A1 (en) Process for the racemisation of an intermediate useful in the preparation of paroxetine
AU2002338757A1 (en) Method for finding novel active ingredients having androgen-type properties